GMAB
Genmab ASNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$17.07B
P/E Ratio
17.95
EPS
$1.54
Beta
0.74
52W High
$35.43
52W Low
$17.57
50-Day MA
$28.91
200-Day MA
$28.16
Dividend Yield
—
Profit Margin
25.90%
Forward P/E
16.29
PEG Ratio
1.75
About Genmab AS
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Fundamentals
| Revenue (TTM) | $3.72B |
| Gross Profit (TTM) | $3.48B |
| EBITDA | $1.29B |
| Operating Margin | 23.00% |
| Return on Equity | 17.50% |
| Return on Assets | 8.10% |
| Revenue/Share (TTM) | $5.99 |
| Book Value | $9.49 |
| Price-to-Book | 2.89 |
| Price-to-Sales (TTM) | 4.59 |
| EV/Revenue | 5.5 |
| EV/EBITDA | 15.31 |
| Quarterly Earnings Growth (YoY) | -94.40% |
| Quarterly Revenue Growth (YoY) | 3.00% |
| Shares Outstanding | $613.91M |
| Float | $60.89M |
| % Insiders | 0.00% |
| % Institutions | 12.12% |
Analyst Ratings
Consensus ($37.14 target)
8
Buy3
HoldData last updated: 4/8/2026